WHO prequalification
Generated by GPT-5-miniExpansion Funnel Raw 68 → Dedup 0 → NER 0 → Enqueued 0
| WHO prequalification | |
|---|---|
| Name | WHO prequalification |
| Formation | 2001 |
| Headquarters | Geneva |
| Parent organization | World Health Organization |
WHO prequalification is a United Nations–linked evaluation mechanism administered by the World Health Organization in Geneva that assesses medicines, vaccines, diagnostics, and other health commodities for procurement by United Nations agencies and partners. It aims to ensure that products supplied to United Nations Children's Fund, United Nations Population Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, the Vaccine Alliance and other international purchasers meet internationally accepted standards of quality, safety and efficacy. The programme interacts with national regulatory authorities such as the European Medicines Agency, U.S. Food and Drug Administration, National Medical Products Administration (China), and regional bodies like the African Union regulatory initiatives.
Overview
The prequalification mechanism was established to provide assurance to large buyers including United Nations Relief and Works Agency for Palestine Refugees in the Near East, World Bank, Médecins Sans Frontières, and bilateral donors such as United States Agency for International Development and Department for International Development (United Kingdom) that products conform to standards comparable to those enforced by stringent regulators. It operates alongside initiatives like the Medicines Patent Pool and complements regulatory reliance strategies used by authorities including Health Canada, Therapeutic Goods Administration (Australia), and the Swissmedic. The programme publishes lists and public assessment reports that inform procurement decisions across humanitarian responses such as those to the Ebola virus epidemic in West Africa and the COVID-19 pandemic.
Scope and Eligibility
Prequalification covers finished pharmaceutical products, active pharmaceutical ingredients, vaccines, in vitro diagnostics, vector control products, and immunization devices. Eligible applicants include multinational manufacturers such as GlaxoSmithKline, Pfizer, Johnson & Johnson, as well as generic producers based in countries with eligible regulatory environments like India, Brazil, South Africa, and China. Procurement partners include Pan American Health Organization, UNICEF Supply Division, International Committee of the Red Cross, and regional procurement mechanisms such as the African Union Development Agency. Products used in responses to outbreaks like Zika virus or H1N1 influenza can be prioritized for accelerated assessment under emergency frameworks.
Application and Assessment Process
Manufacturers submit dossiers following technical guidance aligned with standards from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, the Codex Alimentarius Commission for some diagnostics, and WHO normative guidance documents. The assessment includes dossier review, Good Manufacturing Practice inspections comparable to those by Inspectorate for Medicines of the European Directorate for the Quality of Medicines & HealthCare and batch testing in WHO-designated laboratories often collaborating with national reference labs like those at Centers for Disease Control and Prevention. Decisions on prequalification involve expert advisory committees that include specialists from agencies such as European Centre for Disease Prevention and Control and national ministries of health from countries including Kenya, Nigeria, and India.
Quality, Safety and Efficacy Standards
Standards applied are drawn from pharmacopoeias including the British Pharmacopoeia, United States Pharmacopeia, and regional standards harmonization efforts such as the Pharmacopeial Discussion Group. Clinical efficacy requirements reference pivotal trials listed in registries like ClinicalTrials.gov and ethical oversight consistent with declarations such as the Declaration of Helsinki. Safety assessments consider pharmacovigilance systems exemplified by the Uppsala Monitoring Centre and facility inspections evaluate compliance with Good Manufacturing Practice guidance used by regulators like Medicines and Healthcare products Regulatory Agency.
Post-qualification Surveillance and Compliance
After listing, products are subject to post-market surveillance coordinated with partners including World Health Organization Regional Office for Africa, World Health Organization Regional Office for the Americas, and procurement bodies like UNFPA Supplies. Compliance mechanisms involve periodic reinspection, adverse event reporting linked to systems such as the Vaccine Adverse Event Reporting System framework, and corrective actions comparable to regulatory recalls handled by agencies like the Food and Drug Administration. The programme also engages with initiatives such as the Global Health Cluster during humanitarian crises to monitor product performance.
Impact and Global Use
Prequalified products are widely procured by UNICEF, Global Fund, Gavi, and bilateral donors, influencing market access for producers from regions including Southeast Asia, Latin America, and Sub-Saharan Africa. The mechanism has been instrumental in scaling up access to antiretrovirals during the HIV/AIDS pandemic response, increasing supply of vaccines during polio eradication campaigns, and enabling procurement of diagnostics in outbreaks like Ebola virus disease and COVID-19 pandemic. It shapes procurement tenders run by entities such as UNOPS and national pooled procurement mechanisms including the Eastern Caribbean Drug Service.
Criticisms and Reforms
Critics cite challenges including perceived delays relative to reliance on stringent regulators like the European Medicines Agency or U.S. Food and Drug Administration, potential bottlenecks for small and medium-sized manufacturers in India and China, and resource constraints within WHO. Reforms and proposals have drawn on examples from regulatory convergence efforts such as the International Coalition of Medicines Regulatory Authorities and WHO initiatives to streamline reliance and expedite pathways during public health emergencies like the 2014–2016 Ebola epidemic in West Africa and the COVID-19 pandemic. Discussions involve stakeholders including Bill & Melinda Gates Foundation, Clinton Health Access Initiative, and national ministries of health to enhance transparency, capacity building, and faster access to essential health commodities.